Close
Solutions
Online Inquiry
Global Services

CAR-T Therapy-associated CRS Management

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

CAR-T (Chimeric Antigen Receptor T-cell) therapy has revolutionized the treatment of various types of cancer, offering a promising avenue for patients with limited or no other treatment options. However, the success of CAR-T therapy is accompanied by the challenge of managing side effects, particularly Cytokine Release Syndrome (CRS). CRS is a systemic inflammatory response that can occur following CAR-T cell infusion and is a critical concern in the field of CAR-T therapy. Creative Biolabs, with our extensive experience and expertise, provides a specialized CAR-T Therapy-associated CRS assay service to address this crucial aspect of CAR-T treatment.

Management of CAR T-related CRS

The goal of the management of CRS is to avoid harmful toxicities while maximizing the anti-tumor effect of cellular therapy. Location of care, supportive care, anti-IL-6 therapy, and glucocorticoids are four major approaches. The technical difficulties and cost inherent to real-time monitoring of serum cytokines have precluded the clinical application of this methodology to identify evolving CRS. At present, the use of C-reactive protein (CRP), which is made by hepatocytes in response to IL-6, becomes a laboratory marker of CRS onset and severity.

Fig.1 Potential pathophysiology of CAR T-cell mediated CRS. (Schubert, et al., 2020)Fig.1 Potential pathophysiology of CAR T-cell mediated CRS.1

Our Comprehensive CRS Assay Service

Creative Biolabs' CAR-T Therapy-associated CRS assay service is designed to assist researchers, clinicians, and pharmaceutical companies in assessing and managing CRS associated with CAR-T therapies. Our service comprises various components:

  • Cytokine Profiling
    We employ cutting-edge techniques to quantify a panel of cytokines, including but not limited to IL-6, IFN-γ, tumor necrosis factor-alpha (TNF-α), and interleukin-10 (IL-10). This comprehensive cytokine profiling allows for early detection and monitoring of CRS.
  • Immune Cell Analysis
    Understanding the dynamics of immune cell populations is crucial in assessing the severity of CRS. Our service includes immune cell analysis to monitor changes in T cell subsets, macrophages, and other immune cells during the course of treatment.
  • Biomarker Identification
    Identifying specific biomarkers associated with CRS can aid in early diagnosis and targeted intervention. Creative Biolabs' expertise in biomarker discovery ensures that potential indicators of CRS are thoroughly investigated.
  • Customized Assays
    We recognize that each CAR-T therapy is unique, and the risk of CRS may vary. Therefore, we offer customizable assays tailored to your specific CAR-T product, ensuring that the assay is optimized for your needs.

Features of Our Service

Creative Biolabs has multiple cytokine analysis platforms such as the Luminex multiplex platform, multi-analyte profiling platform, and cytokine profiling array. Each platform possesses its unique advantages. According to your project, we will select the appropriate technology and suitable assays combination to help you obtain higher-quality scientific research data. Besides, we also provide various cytokine profiling antibody array products for protein expression profiling of cytokines and related biomarkers.

  • Early Identification Service
  • Toxicity Assessment Service
  • Research Model Development
  • In Vitro and In Vivo Assay
  • Highlighted CRS Technology Platform

Please contact us for more information about the different assays or services that are available to support your programs.

Reference

  1. Schubert, M. L.; et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of Oncology. 2020.
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.